CagriSema in people living with obesity and cardiovascular diseases

Trial ID:
Athena Philis-Tsimikas, M.D.
The REDEFINE 3 study is evaluating the investigational use of the combination of cagrilinitide and semaglutide (CagriSema) to help treat obesity and impact cardiovascular risk factors. The overall goal is to investigate the long-term safety of CagriSema on the cardiovascular system.
• Have had a stroke, a heart attack (myocardial infarction), <br> or have poor circulation (peripheral arterial disease) <br>• Be 55 years of age or older <br>• Be living with obesity (BMI = 30 kg/m2 ) <br>• Be able to attend regular clinic visits and receive phone <br> calls over a period of 3 years<br>• Meet all other eligibility criteria

Contact Info:

  • Isabel Garcia, RN
  • 858-309-2602